Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA

 Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA

Sarepta Signs an Exclusive Global (Except EU) License Agreement with Lysogene for LYS-SAF302 to Treat MPS IIIA

Shots:

  • Lysogene to get $26M (€22M) upfront cash with equity investment of $2.5M (€2.2M) at a 30% premium, receive development, regulatory, and commercial milestone payments ~$125 M (€108M) with royalties on sales of product
  • Sarepta will get hold of exclusive commercial rights to LYS-SAF302 in the US and and has an option to license CNS Gene therapy candidates for $19M(€16M) & Lysogene will have marketing rights in EU
  • LYS-SAF302 is an AAV-mediated gene therapy candidate to replace SGSH gene with a healthy gene. In Q4’18 Lysogene will onset the completion of trial while Sarepta will be undertake global manufacturing rights of LYS-SAF302 and supply Lysogene for its territory

Click here to read full press release/ article | Ref: Sarepta Therapeutics | Image: The Business Journals

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post